AI English summary of an SEC filing — figures as filed
Becton Dickinson BDXBecton Dickinson said Richard E. Byrd, Executive Vice President and President of the Interventional segment, informed the company of his intention to retire on April 6, 2026.
Key points
AI summaryBecton Dickinson said Richard E. Byrd, Executive Vice President and President of the Interventional segment, informed the company of his intention to retire on April 6, 2026.
The company said Byrd will remain in his role through June and intends to name a successor prior to his retirement date.
Becton Dickinson said in a press release that Byrd has been with BD for approximately 25 years and has served as President of the Interventional Segment since September 2022. It said that prior to joining BD in 2004, he held various leadership and engineering positions in the medical device and advanced technology sectors.
The company said Byrd served as worldwide president of Medication Delivery Solutions and Preanalytical Systems. Chairman Tom Polen noted that Byrd expanded BD's leadership in Vascular Access Management and led critical manufacturing scale-up efforts during the COVID-19 pandemic.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Interventional Segment President Announces Retirement
Becton Dickinson said Richard E. Byrd, Executive Vice President and President of the Interventional segment, informed the company of his intention to retire on April 6, 2026.
Source · Based on the filing body and exhibits
To Remain in Role Through June; Successor to Be Named
The company said Byrd will remain in his role through June and intends to name a successor prior to his retirement date.
Source · Based on the filing body and exhibits
Byrd's Career at Becton Dickinson
Becton Dickinson said in a press release that Byrd has been with BD for approximately 25 years and has served as President of the Interventional Segment since September 2022. It said that prior to joining BD in 2004, he held various leadership and engineering positions in the medical device and advanced technology sectors.
Source · Based on the filing body and exhibits
Prior Roles and Company Achievements
The company said Byrd served as worldwide president of Medication Delivery Solutions and Preanalytical Systems. Chairman Tom Polen noted that Byrd expanded BD's leadership in Vascular Access Management and led critical manufacturing scale-up efforts during the COVID-19 pandemic.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…